A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia.

Inclusion Criteria:

- Men and women with recurrent surface immunoglobulin positive B cell non-Hodgkin's
lymphoma (NHL) according to WHO classification (including, but not limited to,
CLL/SLL, Waldenström's macroglobulinemia [WM], mantle cell lymphoma [MCL], and
diffuse large B cell lymphoma [DLBCL) who have met requirements for roll over from
their parent protocol and want to continue study drug.

- Female subjects of childbearing potential must have a negative serum or urine
pregnancy test within 3 days of the first dose of study drug and agree to use dual
methods of contraception during the study and for 1 month following the last dose
with study drug. Post menopausal females (>45 years old and without menses for >1
year) and surgically sterilized females are exempt from this criterion.

- Male subjects must use an effective barrier method of contraception during the study
and for 3 months following the last dose if sexually active with a female of
childbearing potential.

- Willing and able to participate in all required evaluations and procedures in this
study protocol including swallowing capsules without difficulty

- Ability to understand the purpose and risks of the study and provide signed and dated
informed consent and authorization to use protected health information (in accordance
with national and local patient privacy regulations).

Exclusion Criteria:

- A life-threatening illness, medical condition or organ system dysfunction which, in
the investigator's opinion, could compromise the subject's safety, interfere with the
absorption or metabolism of PCI-32765 PO, or put the study outcomes at undue risk

- Known history of Human Immunodeficiency Virus (HIV) or active infection with
Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or any uncontrolled active
systemic infection.

- Lactating or pregnant